F2G raises $60.8m to support late-stage antifungal clinical programme
Funding will support development of novel antifungal asset olorofim
Read More
Tag: F2G
Manchester biotech’s novel antifungal awarded Orphan status
Manchester, UK-based biotech F2G is celebrating news that its lead clinical candidate, the antifungal F901318, has been awarded Orphan drug designation in Europe.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
